CN105348183A - Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom - Google Patents
Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom Download PDFInfo
- Publication number
- CN105348183A CN105348183A CN201510638931.9A CN201510638931A CN105348183A CN 105348183 A CN105348183 A CN 105348183A CN 201510638931 A CN201510638931 A CN 201510638931A CN 105348183 A CN105348183 A CN 105348183A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- operation low
- low fever
- gynecologic operation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 230000002980 postoperative effect Effects 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- -1 microgranules Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating a gynecology-and-obstetrics postoperative low-fever symptom. The pharmaceutical composition contains an effective dose of compound and pharmaceutically-acceptable carrier, wherein the compound has a structure represented by a formula shown in the description. The compound of the pharmaceutical composition has a remarkable effect on pathogenic bacteria causing the gynecology-and-obstetrics postoperative low-fever symptom and can be developed into clinically-effective novel pharmaceutical compositions.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of post gynecologic operation low fever.
Background technology
Post gynecologic operation low fever is common clinical frequently-occurring disease, and the cause of disease is many caused by cause pathogeny imcrobe infection, causes the pathogenic micro-organism of infection to mainly contain bacterium, virus and mycoplasma, chlamydozoan.Find after deliberation, in the secretory product at patient infection position, various pathogens detected, find that in the recent period Hai Shi faecalis ATCC8043 is also one of pathogenic bacterium wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of post gynecologic operation low fever.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of post gynecologic operation low fever, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of post gynecologic operation low fever, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment post gynecologic operation low fever, and this compound has having structure:
Preferably, described post gynecologic operation low fever is caused by Hai Shi faecalis ATCC8043.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition Hai Shi faecalis ATCC8043, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing post gynecologic operation low fever, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition Hai Shi faecalis ATCC8043
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of compound is:
For examination bacterial classification Hai Shi faecalis ATCC8043 purchased from Fu Xiang bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Hai Shi faecalis ATCC8043 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.07 gram, add 5000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of Hai Shi faecalis ATCC8043 is 14.32mm, and this shows that target compound has the effect of extremely strong suppression Hai Shi faecalis ATCC8043.
Claims (9)
1. treat a compound for post gynecologic operation low fever, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for post gynecologic operation low fever, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of post gynecologic operation low fever according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of post gynecologic operation low fever according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of post gynecologic operation low fever according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of post gynecologic operation low fever according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment post gynecologic operation low fever, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described post gynecologic operation low fever is caused by Hai Shi faecalis ATCC8043.
9. the purposes of compound in the medicine of preparation vitro inhibition Hai Shi faecalis ATCC8043, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510638931.9A CN105348183A (en) | 2015-09-29 | 2015-09-29 | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510638931.9A CN105348183A (en) | 2015-09-29 | 2015-09-29 | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105348183A true CN105348183A (en) | 2016-02-24 |
Family
ID=55324270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510638931.9A Pending CN105348183A (en) | 2015-09-29 | 2015-09-29 | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105348183A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110096A (en) * | 2016-08-23 | 2016-11-16 | 杜娟 | A kind of pharmaceutical composition treating post gynecologic operation low fever |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000159665A (en) * | 1998-11-27 | 2000-06-13 | Nippon Kayaku Co Ltd | Preventive or therapeutic agent of rheumatism |
| WO2007064691A1 (en) * | 2005-12-02 | 2007-06-07 | Nabil Habib Lab | Treatment of cancer and other diseases |
-
2015
- 2015-09-29 CN CN201510638931.9A patent/CN105348183A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000159665A (en) * | 1998-11-27 | 2000-06-13 | Nippon Kayaku Co Ltd | Preventive or therapeutic agent of rheumatism |
| WO2007064691A1 (en) * | 2005-12-02 | 2007-06-07 | Nabil Habib Lab | Treatment of cancer and other diseases |
Non-Patent Citations (5)
| Title |
|---|
| 何礼贤等: "《塑料助剂与配方设计技术 第3版》", 31 July 2010, 北京：中国医药科技出版社 * |
| 李影林: "《临床医学检验手册》", 31 August 1987, 长春：吉林科学技术出版社 * |
| 李耀武: "李耀武", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 李耀武等: "作用于秋水仙碱位点的微管蛋白抑制剂的结合模式研究与结构模型的构建", 《化学学报》 * |
| 李西平等: "中西医结合治疗妇产科术后低热症100例效果观察", 《吉林医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110096A (en) * | 2016-08-23 | 2016-11-16 | 杜娟 | A kind of pharmaceutical composition treating post gynecologic operation low fever |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105330610A (en) | Medicine composition for treating gingivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |